Havasu, You may have missed some of the ongoing
Post# of 148160
(Total Views: 575)
Posted On: 01/26/2021 9:17:47 PM
Havasu,
You may have missed some of the ongoing discussions, but the issue with data verification in a nutshell is that Amarex has to examine the data in great detail, contact the trial site investigators to verify any data that appears to be incorrect and obtain any missing data.
This is not instantaneous.
The trial site investigators will need to review clinical records, find the missing information or verify subject information, and report this back to Amarex.
Expand this for 394 patients, each with many hundred of data points, all spread among 18 trial sites with multiple participating clinicians are each.
Like nearly any job in the world, this seems easy, until one actually has to perform the job.
Most of us (myself included) have not had sufficient exposure to the hard work and tremendous attention to detail that goes into scientific research, especially at this level.
I hope this clarifies the challenge.
You may have missed some of the ongoing discussions, but the issue with data verification in a nutshell is that Amarex has to examine the data in great detail, contact the trial site investigators to verify any data that appears to be incorrect and obtain any missing data.
This is not instantaneous.
The trial site investigators will need to review clinical records, find the missing information or verify subject information, and report this back to Amarex.
Expand this for 394 patients, each with many hundred of data points, all spread among 18 trial sites with multiple participating clinicians are each.
Like nearly any job in the world, this seems easy, until one actually has to perform the job.
Most of us (myself included) have not had sufficient exposure to the hard work and tremendous attention to detail that goes into scientific research, especially at this level.
I hope this clarifies the challenge.
(11)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼